Article Text

Download PDFPDF
Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer
  1. Archana R. Simmons, PhD,
  2. Charlotte H. Clarke, PhD,
  3. Donna B. Badgwell, PhD,
  4. Zhen Lu, MD,
  5. Lori J. Sokoll, PhD,
  6. Karen H. Lu, MD,
  7. Zhen Zhang, PhD,
  8. Jr Robert C. Bast, MD and
  9. Steven J. Skates, PhD
  1. * Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX;
  2. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD;
  3. Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX; and
  4. § Department of Biostatistics, Massachusetts General Hospital, Boston, MA.
  1. Address correspondence and reprint requests to Robert C. Bast, Jr, MD, University of Texas M.D. Anderson Cancer Center, 1400 Pressler St, Unit 1439, Houston, TX 77230. E-mail: rbast{at}mdanderson.org.

Abstract

Objectives Longitudinal multimarker combinations have the potential to improve sensitivity while maintaining the high specificity required for the early detection of ovarian cancer. The use of multiple markers to improve sensitivity over cancer antigen 125 (CA125) in longitudinal algorithms for early ovarian cancer detection requires the selection of markers with optimal discriminatory power and low longitudinal variance relative to disease-initiated changes. Our objective was to identify a multimarker panel suitable for ovarian cancer, where each individual marker has its own baseline, permitting longitudinal algorithm development.

Materials and Methods In this retrospective study, we measured CA125, human epididymis protein 4 (HE4), matrix metalloproteinase-7 (MMP-7), CA72-4, CA19-9, CA15-3, carcinoembryonic antigen, and soluble vascular cell adhesion molecule (sVCAM) concentrations using immunoassays in pretreatment sera from 142 stage I ovarian cancer cases and 5 annual samples each from 217 healthy controls. After random division into training and validation sets, all possible biomarker combinations were explored exhaustively using linear classifiers to identify the panel with the greatest sensitivity for stage I disease at a high specificity of 98%. To evaluate longitudinal performance of the individual markers, the within-person over time and the between-person coefficient of variation (CV) were estimated. Hierarchical modeling across women of log-concentrations enabled the borrowing of information across subjects to moderate variance estimates given the small number of observations per subject.

Results The 4-marker panel comprising CA125, HE4, MMP-7, and CA72-4 performed with the highest sensitivity (83.2%) at 98% specificity. The within-person CVs were lower for CA125, HE4, MMP-7, and CA72-4 (15%, 25%, 25%, and 21%, respectively) compared with their corresponding between-person CV (49%, 20%, 35%, and 84%, respectively) indicating baselines in healthy volunteers. After simple log-transformations, the within-volunteer variation across volunteers was modeled with a normal distribution permitting parsimonious hierarchical modeling.

Conclusions The multiplex panel chosen is suitable for the early detection of ovarian cancer and the individual markers have their own baseline permitting longitudinal algorithm development.

  • Ovarian cancer
  • Early detection
  • Multiple marker
  • Longitudinal biomarker

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.